early asset development

This page shows the latest early asset development news and features for those working in and with pharma, biotech and healthcare.

Redefining launch excellence in 2017

Now, more so than ever, launch preparation and commercial involvement should begin as early as possible in the asset’s development. ... It is crucial that these teams connect as early as possible, because whether it is intentional or not, the

Latest news

Cello Health expands with Defined Health acquisition

Defined Health will work closely with its new parent company in early asset development and commercialisation, with a particular focus on defining value for early-stage compounds. ... offer our clients through the full span of the development process

More from news
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest Intelligence

Assessing early market opportunity

To successfully develop and launch an asset it’s crucial to identify and define the commercial value early in the process. ... On the 19. th. April Cello Health, in association with PMGroup, will host a free webinar which will discuss the background
Managing value: Why early asset development and commercialisation are important

Managing value: Why early asset development and commercialisation are important. Realising the full value of your asset - clinically and commercially - means thinking beyond the pure scientific value, even at the very ... Unsurprisingly, slightly more
The value of early asset development and commercialisation

On July 13 Cello Health, in association with PMGroup, will host a free webinar on the value of early asset development and commercialisation. ... It will follow the asset development journey, defining value from both a financial and clinical perspective,

More from intelligence
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest from PMHub

Managing value: Why early asset development and commercialization is important

Managing value: Why early asset development and commercialization is important. Realising the full value of your asset – clinically and commercially – means thinking beyond the pure scientific value, even at the very ... Unsurprisingly, slightly more

More from PMHub
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Associate Medical Director: Salary TBC

Senior Account Manager - Med Comms: Highly Competitive Salary &Benefits

Senior Systematic Review Analyst - Oxford: Negotiable

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Account Manager, Healthcare Advertising: Salary TBC

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Project / Account Manager (Medical Education): Salary TBC

Account Director – Global Healthcare PR: Salary TBC

Director Healthcare PR Communications: Salary TBC

Senior Account Manager / Account Director - Med Comms: Great salary and benefits

Medical Strategic Director, Healthcare Advertising Agency: Salary TBC

Director – Head of Public Affairs: Neg

Experienced Editor, London, Medical Communications: Competitive package

Associate Medical Director: Highly Competitive

Senior Medical Writer (Remote Working): Competitive Salary Offered

Scientific Team Lead: Competitive Salary

Editorial Director – Medical Education: Neg

Account Manager- Manchester, Macclesfield or Glasgow: Negotiable

SENIOR MEDICAL WRITER IN ONCOLOGY: Up to £60, 000.00 pension bonus

Account Director: Negotiable

Scientific Director: Highly Competitive Salary &Benefits

Account Manager, Healthcare Communications: £32, 000 - £40, 000 benefits

Consultant Health Economics - London / Oxford: Negotiable

Senior Account Executive – Medical Communications: Salary TBC

Lead Medical Copywriter, Healthcare Brand Communications, London: Excellent package

Subscribe to our email news alerts

PMHub

Add my company

GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe: Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
Retaining reader value in plain language summaries of clinical studies: Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?: Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...